Small molecule tyrosine kinase inhibitors directed against mutated EGFR or ALK fusion proteins have transformed treatment outcomes for the ~10% and ~4%, respectively, of Western NSCLC patients whose tumors are driven by one of these activated oncogenes. Here, ALK is linked to non-small cell lung carcinoma.